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Background Influenza is associated with an increase in the risk of cardiac and other vascular events. Observational
data and small randomized trials suggest that influenza vaccination may reduce such adverse vascular events.
Research Design and Methods In a randomized controlled trial patients with heart failure are randomized to
receive either inactivated influenza vaccine or placebo annually for 3 years. Patients aged ≥18 years with a clinical diagnosis
of heart failure and NYHA functional class II, III and IV are eligible. Five thousand patients from 10 countries where influenza
vaccination is not common (Asia, the Middle East, and Africa) have been enrolled. The primary outcome is a composite of the
following: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalizations for heart failure using
standardized criteria. Analyses will be based on comparing event rates between influenza vaccine and control groups and will
include time to event, rate comparisons using Poisson methods, and logistic regression. The analysis will be conducted by
intention to treat i.e. patients will be analyzed in the group in which they were assigned. Multivariable secondary analyses to
assess whether variables such as age, sex, seasonality modify the benefits of vaccination are also planned for the primary
outcome.
Conclusion This is the largest randomized trial to test if influenza vaccine compared to control reduces adverse vascular
events in high risk individuals.
Trial registration number Clinicaltrials.gov NCT02762851 (Am Heart J 2019;212:36-44.)
Background
Cardiovascular disease is a leading cause of death
globally estimated to be responsible for ~ 17 million
deaths annually.1 Cardiovascular disease and stroke
account for nearly one third of all deaths and are a major
cause of hospitalization.2,3 Patients with congestive heart
failure (CHF) are at particularly high risk with 50% dying
within 5 years. An additional one third of patients with
CHF will experience a myocardial infarction (MI), stroke,
or hospitalization for CHF annually.4-8
Observational studies have established an association
between influenza infection and major adverse vascular
events. Mechanisms that have been postulated to explain
this increased risk after an influenza infection include the
precipitation of plaque rupture,9 endothelial dysfunc-
tion,10,11 reactivation of other latent infections leading to
plaque rupture,12 fever-associated tachycardia,13 and
metabolic derangements related to infection, including
elevation of triglycerides and serum glucose levels.14-15
It follows that vaccinating a high-risk group such as
patients with CHF against influenza may prevent adverse
vascular events. Studies examining influenza vaccination
and vascular events however have shown conflicting
results.16-27
We conducted an observational study using databases
from two large clinical trials,27 indicating that influenza
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vaccination may be associated with a reduction of major
adverse vascular events. Using prospectively collected
data from randomized controlled trials, we performed an
analysis to determine the association between influenza
vaccination and major adverse vascular events. The
summary OR for the four adjusted odds ratios from the
influenza seasons was 0.65 (95% CI 0.58-0.74, P b .001),
but there was statistically significant heterogeneity (P =
.003). There have been three recent studies, all using case
only observational designs, which have reported a strong
association between influenza and cardiac events.28-30
There have been four systematic reviews of random-
ized trials on the effect of influenza vaccination on
major adverse vascular events.31-34 The most recent, an
updated Cochrane review, included eight randomized
trials, of which four focused specially on cardiovascular
outcomes in patients within known cardiovascular
disease while four focused on general populations
where cardiovascular outcomes were included as part
of the safety analyses.34 Data from three pooled RCTs
comparing influenza vaccine to placebo or control
demonstrate a relative risk of 0.63 (95% CI, 0.29-01.35)
with respect to major adverse coronary events cardio-
vascular death was reported to be significantly reduced
when four cardiovascular specific trials were pooled,
relative risk 0.45, 95%CI 0.26 to 0.76). Of these four trials,
only two had point estimates showing a risk reduction for
cardiovascular death, the other two had point estimates
close to 1. The three trials that reported cardiovascular
mortality as part of safety analyses did not show
differences but were underpowered due to low event
rates.34 None of the included trials fulfilled all criteria
with respect to low risk of bias. Together these results
emphasize uncertainty of the clinical trial data and the
need for higher quality evidence.
Because of the strong possibility of bias, results from
previous observational studies and small trials need to be
independently confirmed in a prospective, randomized trial.
While several guidelines endorse influenza vaccination for
patients with chronic cardiac disease, these guidelines are
largely based on observational data and expert opinion, with
data lacking from adequately powered, prospective, ran-
domized trials. Therefore, it is not surprising that actual
vaccination rates remain low. Clinical equipoise exists as to
whether influenza vaccine in fact prevents cardiovascular
events in patients with CHF. Consequently, a large
randomized controlled trial with the power to detect or
exclude moderate treatment effects is needed to reliably
address the question. Given that 80% of CVD occur in
populations in low- andmiddle-income countries, a trial with
enrolment of patients from these countries have the
potential to have an important global impact.
Trial design and methods
This study is a multi-center, randomized, placebo controlled,
trial funded by the Joint Global Health Trials Scheme which in
turn is funded by the UK Department for International
Development, the Medical Research Council, the National
Institute for Health Research and Wellcome Trust.
Participants at high-risk for vascular events are random-
ized to inactivated influenza vaccine (VAXIGRIP ®) or
placebo and followed prospectively over three influenza
seasons (Figure 1). The trial is being conducted by an
international network of sites (Table I).
Although patients in the studywere not randomly selected
from the participating countries heart failure population, we
believe that they are a reasonable representation based on
study sites that include urban and rural centers as well as
primary care practitioners and specialists, and sites from
regions not previously well represented in the literature as
we have previously established.35 The trial has been
registered at Clinicaltrials.gov (NCT02762851). The authors
are solely responsible for the design and conduct of this
study, all study analyses, the drafting and editing of the paper
and its final contents.
Study population
The eligibility criteria are shown in Table II. Patients
aged ≥18 years with a clinical diagnosis of heart failure
and NYHA functional class II, III and IV are eligible. We
decided to enroll heart failure patients because they area
a high-risk population for heart disease as well as stroke.
Moreover, this population allows for us to test whether
influenza vaccination reduces hospitalization for heart
failure both as part of the composite primary outcome as
well as a secondary outcome alone. This is justified on the
basis that it has been well documented that influenza is an
important risk factor for heart failure hospitalization.36
Patients are randomized to either influenza vaccine or
placebo. Given that there is no evidence that two influenza
vaccinations results in harm, participants can obtain
influenza vaccination from their primary care physicians
outside of the study if prescribed by them. Thosewith any of
the following are excluded: a) anaphylactic reaction to a
previous dose of influenza vaccine, b) known IgE-mediated
hypersensitivity to eggs manifested as hives, swelling of the
mouth and throat, difficulty in breathing, hypotension, or
shock, c) Guillain-Barré syndrome within 8 weeks of a
previous influenza vaccine, d) anaphylactic reaction to
neomycin.We also exclude patientswho have had influenza
vaccine (by self-report) in two of the three previous years.
This is because such patients are more likely to receive the
influenza vaccine annually andwill be more likely to request
it outside of the trial. Patients with severe valvular disease
that are candidates for surgical or percutaneous valve repair
or replacement are also excluded.
Baseline characteristics of participants enrolled to date
are shown in Table III.
Study objectives
The primary objective is to assess if influenza vaccina-
tion compared to placebo reduces a composite outcome
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of cardiovascular death, non-fatal myocardial infarction,
non-fatal stroke and hospitalizations for heart failure using
standardized criteria. This is a clinically important
outcome that is easily measured and one which has
been used in large clinical trials of CVD and heart
failure.37-39 This outcome is a composite of the most key
outcomes relevant to what we are testing in the
intervention.
The secondary objectives are to assess whether
influenza vaccine reduces cardiovascular death, non-
fatal myocardial infarction, non-fatal stroke, hospitaliza-
tions for heart failure, all cause hospitalizations, and all
cause death alone. In a sub-group of participants, the
rates of influenza infection will be assessed using
serology. This will be defined by ≥ 4-fold increase in
influenza-specific hemagglutinin inhibition assay titer
between baseline and end of season serum samples,
taking into account the effect of the vaccine. The effect of
influenza vaccination on Influenza-like illness (defined by
cough and fever), lower respiratory tract infection
(including exacerbation of chronic pulmonary disease)
or pneumonia will also be assessed.
Study design
A multi-center, randomized, placebo controlled, trial.
Participants at high-risk for vascular events in low to
middle income countries will be randomized to inacti-
vated influenza vaccine (VAXIGRIP ®) or placebo and
followed prospectively over three influenza seasons. The
primary outcome is a composite of cardiovascular (CV)
death, non-fatal myocardial infarction (MI), non- fatal
stroke, and hospitalization for CHF. We hypothesize that
the intervention will lead to an 18 % risk reduction in the
Figure 1
Trial flow diagram.
Table I. List of study countries and current enrollment figures by
country as of January 21, 2019
Country Enrollment
Philippines 708
Uganda 59
Mozambique 319
Kenya 115
Zambia 503
Nigeria 1011
India 1175
China 694
Saudi Arabia 311
United Arab Emirates 20
Total 4915
Table II. Eligibility criteria
Inclusion Exclusion
Age ≥18 years Anaphylactic reaction to a
previous dose of TIV
NYHA class II, III, and IV Known IgE-mediated hypersensitivity
to eggs manifested as hives,
swelling of the mouth and throat,
difficulty in breathing, hypotension, or shock
Guillain-Barré syndrome within eight
weeks of a previous influenza vaccine
Anaphylactic reaction to neomycin
Patients who have had influenza vaccine
in two of three previous years
Patients who have had influenza vaccine
in two of three previous years
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primary outcome. The study flow diagram is shown in
Figure 1.
Study sites and enrollment
For each of the participating countries, one center
serves as National Coordination Office (NCO). These
NCOs are considered national centers of excellence in
cardiovascular clinical trials and are led by experienced
cardiologists who are leaders in conducting clinical trials.
Each of these NCOs identified local sites for recruitment
of participants in the clinical trial. The NCOs are in
countries that all have a b 15% uptake of influenza
vaccine, enhancing feasibility of this randomized trial
which compares a strategy of routine use of the vaccine
vs no routine use.
Randomization and blinding
Eligible and consenting participants are randomized to
experimental and control armsusing a central randomization
system after patient identification and key clinical data are
provided to a central web-based randomization service. The
trial statistician generated a randomization list, blocked by
site prior to the start of the study such that participants are
assigned at random to oneof the two study groups (influenza
vaccine or placebo), in a 1:1 ratio. A web-based system for
allocationof the vaccinewas set up and shippingof the study
vaccine (influenza vaccine or placebo) to study sites is
coordinated by working with the vaccine manufacturer.
Concealment of allocation is done using a centralized
web-based system. To maintain blinding of the partici-
pants, those allocated to placebo receive a 0.5ml sterile
saline vaccine to mimic the influenza vaccine. Investiga-
tors, study coordinators, outcome adjudicators, and the
data and safety monitoring board are blinded. The study
vaccines are administered by an unblinded study nurse.
The primary outcome of the trial is assessed by research
staff at study centers blinded to allocation by direct
communication with the participant (or next of kin) and
review of medical records.
Study interventions
Experimental (inactivated influenza vaccine): Partici-
pants at high risk for adverse vascular events are
immunized with inactivated trivalent influenza vaccine
(VAXIGRIP® vaccine) recommended for the influenza
season. A 0.5 ml dose of the vaccine is administered
intramuscularly annually for three consecutive influenza
seasons. The inactivated influenza vaccine is adminis-
tered world-wide to prevent influenza and therefore was
selected as the intervention. We selected VAXIGRIP®
vaccine specifically because it is licensed in the countries
selected as study sites. The use of the trivalent vaccine is
pragmatic, that is, trivalent Vaxigrip is the most widely
licensed influenza vaccine in participating countries. The
quadrivalent vaccine adds a second lineage of B influenza.
It is notable that there are no randomized trials of a head
to head comparison between trivalent and quadrivalent
vaccines. Furthermore, the extent to which influenza B
contributes to cardiovascular events is unknown. The
impact of the quadrivalent vaccine would only be during
a year in which the B strain that is circulating is of a
different lineage that the one in the trivalent vaccine.
Control (Saline): Participants at high risk for adverse
vascular events will be immunized with sterile saline. A
Table III. Baseline characteristics of 4871 participants⁎ enrolled as of January 14, 2019.
Variable
Mean Age (years) 57.1
18–35 526/4907 (10.7%)
36–64 2674/4907 (54.5%)
≥ 65 1707/4907 (34.8%)
Sex (Female) 2555/4907 (52.1%)
New York Heart Association Class for Heart Failure
Class II 3411/4907 (69.5%)
Class III 1273/4907 (25.9%)
Class IV 219/4907 (4.5%)
Prior Myocardial Infarction 945/4878 (19.4%)
Depressed left ventricular
Function
3507/4641 (75.6%)
Prior Stroke 391/4878 (8.0%)
Angiotensin converting
Enzyme inhibitor
Reduced Ejection Fraction 1736/3506 (49.5%) Preserved Ejection Fraction
502/1376 (36.5%)
Beta blocker 2232/3506 (63.7%) 633/1376 (46.0%)
Diuretic 2593/3506 (74.0%) 581/1376 (42.2%)
Aldosterone inhibitor 1954/3506 (55.7%) 396/1376 (28.8%)
⁎Since data is still being entered, denominators vary.
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0.5 ml dose is administered intramuscularly annually for
three consecutive influenza seasons.
Safety monitoring
Reactogenicity events at the injection site (soreness at
the site of injection, redness N2 cm, swelling N2 cm, and
limitation of movement) are recorded. Each adverse
event is graded for severity on a five-point scale and its
relationship to study vaccine (associated or not associat-
ed) assessed by the study nurses and the investigators. We
assess for immediate hypersensitivity allergic reactions by
having the vaccination nurse monitor participants for 15
minutes following immunization, as is the general
practice in public health units. Additionally, each
participant that is vaccinated receives a symptom list to
be checked daily for 5 days following vaccination. The
major risk of influenza vaccine, although rare (1 per
200,000 doses), is an anaphylactic reaction, characterized
by hives, swelling of mouth and throat, difficulty
breathing, and low blood pressure. Such a rare event
occurs immediately after injection. However, these
adverse events are known to occur with influenza
vaccination and would not be a problem that would
interfere with implementing the trial.
Timing of vaccination
Participants are recruited and randomized prior to
influenza season. There is considerable variability in the
circulation of the influenza between and within the
countries (e.g. China and India) participating in this
trial.40,41 We use data from WHO and from within the
country to determine optimal timing of influenza
vaccination (i.e. November/December or April/May). In
some African countries, influenza circulates throughout
the year. In these countries, participants are enrolled
either in October to November (a “fall” cohort) and from
April to May (a “spring” cohort). The start of vaccination
is determined by the availability of the influenza vaccine.
Formulations for either the Northern or Southern
hemispheres are used.
Follow-up
Follow-up occurs every six months over the course of
the study. Site investigators schedule clinic visits with
participants to determine whether events occurred in the
previous six months. When this is not feasible, a
telephone call is scheduled. Where a clinic visit or
telephone call with the participant is not feasible (e.g.
death or hospitalization), next of kin are contacted.
Outcome measures
The primary outcome is a composite of cardiovascular
death, non-fatal myocardial infarction, non-fatal stroke
and hospitalizations for heart failure using standardized
criteria. This is a clinically important outcome that is
easily measured and one which we have extensive
experience using in clinical trials. Heart failure diagnosis
is captured by physician report. Cardiovascular death,
non-fatal myocardial infarction, non-fatal stroke, hospital-
izations for heart failure, all cause hospitalizations, and all
cause death, are secondary outcomes. In a sub-study, a
sub-group of participants in selected countries are
assessed for influenza infection using serology. There
will be specimens from 2,000 participants in the
serological sub-study. Using standardized criteria, all
study outcomes will be adjudicated within each coun-
try/site by independent adjudicators who are blinded to
treatment assignment.
Sample size and statistical analyses
Event rates for this study are based on our clinical trial
experience using similar composite primary outcome. In
fact, the ONTARGET and TRANSCEND randomized
controlled trials which provided observational data to
support this proposed trial used adverse vascular events
as a composite outcome. We estimate that using our
primary outcome, which includes hospitalization for
heart failure, 5000 participants will need to be enrolled
and followed over 3 years. This is based on assumptions
that consider the prevention of influenza by the vaccine.
We first assume that 10% of adverse vascular events will
be independent of influenza (250 events in group),
leaving 2250 in each group if we conservatively count
only first events. A 25% attack rate of influenza in the
control group (based on clinical and serologically defined
infection) equates to 562 cases and a similarly defined
15% attack rate in the vaccine group, conservatively
assuming an influenza risk reduction of 40% with the
vaccine, equates to 338 influenza cases in vaccine group.
Assuming that 30% of these influenza infections result in
adverse vascular events results in 168 and 101 adverse
vascular events, respectively. Adding back the 250
adverse vascular events independent of influenza vacci-
nation to each group leads to 418 adverse vascular events
in the control group (418/2500 or 17%) and 351 adverse
vascular events (351/2500 or 14%) in the vaccine group –
for 83% power to detect this difference. Two meta-
analyses are consistent in establishing the vaccine
efficacy of the influenza vaccine as 60%, that is, a 40%
risk reduction in preventing influenza.42,43 Although
there are no direct data that support the assumption
that 30% of influenza infections in high risk patients lead
to adverse vascular events, this figure is in keeping with
what would be expected if the attributable effect of the
influenza vaccine is due to prevention of influenza. Using
the assumptions we present in the paper, the trial is
powered to detect adverse vascular events of 17% in the
control group to 14% in the influenza group. This is less
than the risk reductions which have been predicted by
meta-analyses of previously published randomized con-
trolled trials.42,43 Our experience to date suggests that
receipt of vaccine outside of the study is negligible so
40 Loeb et al
American Heart Journal
June 2019
Downloaded for Anonymous User (n/a) at Aga Khan University Hospital from ClinicalKey.com by Elsevier on October 26, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
would be expected to have no impact on control event
rates or on sample size. Enrollment is shown in Figure 2.
Analyses will be based on comparing event rates
between influenza vaccine and control groups and will
include time to event, rate comparisons using Poisson
methods, and logistic regression. The analysis will be
conducted by intention to treat i.e. patients will be
analyzed in the group in which they were assigned.
Multivariable secondary analyses where variables such as
age, sex, seasonality are assessed independently as
potential risk factors for the primary outcome and
adjusted for in the analysis of the main effects (study
vaccine) will be conducted. Influenza vaccines contain
three antigens which change annually. Although there
typically is a predominant strain that circulates, often
there are co-circulating strains. Because the trial will be
conducted over several seasons it will help ensure that
the effect of a match between the vaccine strain and a
circulating strain can be assessed. The analysis will be
conducted at the end of the study period.
Ethical considerations
There is uncertainty about the benefit of influenza
vaccination to prevent adverse vascular events. Observa-
tional studies cannot adequately address the question
because of confounding. There is also uncertainty about
the non-cardiovascular benefits of the influenza vaccine.
A Cochrane review of influenza vaccine in persons N65
years provided evidence that although the vaccine could
reduce influenza and influenza-like illness, there was
insufficient data to make conclusions about death,
pneumonia, or hospitalization.44 In order to reduce the
possibility of randomizing participants who are routinely
vaccinated against influenza, we excluded participants
who received the influenza vaccine in two of the three
previous years. We also allowed participants to receive
influenza vaccine outside of the trial if they chose to do
so. This way not only is the uptake of influenza vaccine
increased in patients who otherwise would not be
vaccinated, but in fact no one in the trial is denied
vaccination. Ethics approval was obtained from the
research ethics boards of all participating centers prior
to the start of the study.
Data collection, management, and monitoring
Recruitment is based at centers in Asia, Africa and the
Middle East, where it is not common to vaccinate
routinely. Simple data collection forms are completed
and submitted by the site using the internet version of the
DataFax software. Data management for data control and
completeness checks is performed centrally by the PHRI
coordinating center by trained personnel. All data are
kept secure and confidentiality of all study participants is
carefully protected.The quality control process has been
integrated into the overall data management process.
Quality assurance or audit process is performed by staff at
the coordinating center. A sample of participant records
(10%) is audited quarterly using our participant record
audit tool. This retrospective review will focus on the
following indicators: consent forms; eligibility; vaccine
administration and reactogenicity; adverse event/serious
adverse event reporting; study endpoints; missed vacci-
nations and blood draws; signatures, as required; and
study discontinuation. Regulatory records are audited
Figure 2
Cumulative enrollment as of September 1, 2018.
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annually using a regulatory file audit tool. The following
indicators are included during this process: ethics
approvals, safety reports, protocol and consent, sample
CRFs, and monitoring reports.
Oversight for the trial is being conducted by a steering
committee composed of the Principal Investigator and
the National Leaders. A DSMB committee is responsible
for safety oversight of the study (including monitoring of
adverse reactions). The DSMB, composed of a cardiolo-
gist, an infectious disease physician and a biostatistician is
responsible for making recommendations on safety
issues, premature trial termination, and unblinding of
study groups.
Funding source
The Joint Global Health Trials Scheme which is funded
by the UK Department for International Development,
the Medical Research Council, the National Institute for
Health Research and Wellcome Trust. Sanofi Pasteur is
providing the influenza vaccine for the trial.
Discussion
This randomized trial has important implications for the
management of patients at high risk for major adverse
vascular events. Although the influenza vaccine is
recommended annually for groups with diabetes and
cardiovascular disease in many counties, uptake of these
recommendations is relatively low, perhaps because the
current recommendations are not based on robust results
from large well conducted RCTs. Cardiologists in most
jurisdictions do not routinely recommend annual influ-
enza vaccine for their patients as a strategy to reduce
future adverse vascular events such as acute coronary
syndrome or stroke. Apart from lack of evidence, cost,
lack of physician reminders, and insurance coverage may
be other reasons for this. Rigorous demonstration of
influenza vaccine leading to a reduction in major adverse
vascular events would represent a landmark study.
We anticipate that this trial has the potential to
influence management decisions by physicians for
patients at high risk for major vascular events. The
effect size we are testing is comparable to secondary
prevention strategies available and given the fact that a
vaccine is given once annually it is simple and inexpen-
sive. Given the large burden of disease, the possibility to
reduce cardiovascular and stroke related death is a
compelling argument for this trial. If influenza vaccine
is shown to reduce adverse vascular events, it will
represent an important change in how prevention of
adverse vascular events is thought about. The fact that
our primary outcome is a composite, including various
forms of vascular disease, will potentially increase
health benefit.
A unique feature of this randomized trial is that it is
being conducted such in a broad and diverse population.
The study is being conducted in regions where the
epidemiology of influenza is highly variable and this has
been taken into account with respect to timing of the
influenza vaccine. There are two other large randomized
trials assessing the effect of influenza vaccine on
cardiovascular outcomes.45,46 The INVESTED trial is
comparing the effect of a high dose vaccine to a standard
vaccine while the IAMI trial is randomizing patients with
STEMI or non-STEMI undergoing coronary angiography
to influenza vaccine or placebo. Both of these studies are
being conducted in Western countries. Our trial is the
largest placebo-controlled trial conducted to date and is
unique in that it is being conducted in diverse geograph-
ical locations including Asia, Africa, and the Middle East.
A recent study published in the Lancet on the global
burden of influenza estimated that the greatest burden of
death is in southeast Asia and Africa,47 both represented
in our study. In many low and middle- income countries,
the cost of influenza vaccine is prohibitive and as a result
the vaccine is not made publicly available. Despite data
suggesting that the greatest burden of illness is in
southeast Asia and Africa, uptake of influenza vaccine
remains low. The existence of competing risks for death,
such as malaria or tuberculosis in Africa, emphasize that a
significant effect of the influenza vaccine in reducing
adverse vascular events will be compelling to policy-
makers to enable access to influenza vaccine. Our
findings will therefore have important implications for
global health since the results will be generated in low-
and middle-income countries and not extrapolated from
highly developed countries. We recognize that we are not
doing surveillance for influenza in this study as we do not
have the resources. However, we will capture influenza-
like illness that is self-reported, and we are doing
serological sub-study to assess influenza illness.
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